Nancy King to Clinical Trials as Topic
This is a "connection" page, showing publications Nancy King has written about Clinical Trials as Topic.
Connection Strength
1.446
-
King NM. Benefits, harms, and motives in clinical research. Hastings Cent Rep. 2009 Jul-Aug; 39(4):3.
Score: 0.303
-
King NM, Cohen-Haguenauer O. En route to ethical recommendations for gene transfer clinical trials. Mol Ther. 2008 Mar; 16(3):432-8.
Score: 0.277
-
Easter MM, Henderson GE, Davis AM, Churchill LR, King NM. The many meanings of care in clinical research. Sociol Health Illn. 2006 Sep; 28(6):695-712.
Score: 0.249
-
Baker HB, McQuilling JP, King NM. Ethical considerations in tissue engineering research: Case studies in translation. Methods. 2016 Apr 15; 99:135-44.
Score: 0.116
-
King NM, Perrin J. Ethical issues in stem cell research and therapy. Stem Cell Res Ther. 2014 Jul 07; 5(4):85.
Score: 0.107
-
Churchill LR, King NM, Henderson GE. Why we should continue to worry about the therapeutic misconception. J Clin Ethics. 2013; 24(4):381-6.
Score: 0.097
-
Hall MA, Friedman JY, King NM, Weinfurt KP, Schulman KA, Sugarman J. Commentary: Per capita payments in clinical trials: reasonable costs versus bounty hunting. Acad Med. 2010 Oct; 85(10):1554-6.
Score: 0.083
-
Henderson GE, Churchill LR, Davis AM, Easter MM, Grady C, Joffe S, Kass N, King NM, Lidz CW, Miller FG, Nelson DK, Peppercorn J, Rothschild BB, Sankar P, Wilfond BS, Zimmer CR. Clinical trials and medical care: defining the therapeutic misconception. PLoS Med. 2007 Nov 27; 4(11):e324.
Score: 0.068
-
Kipnis K, King NM, Nelson RM. Trials and errors: barriers to oversight of research conducted under the emergency research consent waiver. IRB. 2006 Mar-Apr; 28(2):16-9.
Score: 0.060
-
Henderson GE, Davis AM, King NM. Vulnerability to influence: a two-way street. Am J Bioeth. 2004; 4(3):50-2; discussion W32.
Score: 0.052
-
Kent A, King NM, Cohen-Haguenauer O. Toward a proportionate regulatory framework for gene transfer: a patient group-led initiative. Hum Gene Ther. 2011 Feb; 22(2):126-34.
Score: 0.021
-
Churchill LR, Nelson DK, Henderson GE, King NM, Davis AM, Leahey E, Wilfond BS. Assessing benefits in clinical research: why diversity in benefit assessment can be risky. IRB. 2003 May-Jun; 25(3):1-8.
Score: 0.012